Patents Examined by George W Kosturko
  • Patent number: 10653674
    Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: May 19, 2020
    Assignee: VERSEON CORPORATION
    Inventors: Kevin Michael Short, Son Minh Pham, David Charles Williams, Somalee Datta
  • Patent number: 10632105
    Abstract: The invention relates to the selective targeting of specific ?2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the ?2c receptor subtype using an ?2c specific agonist or by blocking the ?2a receptor subtype using ?2a antagonists. A combination of an ?2c agonist and an ?2a antagonist is also provided for a synergistic effect. Alternatively, a large ?2 agonist can be used in combination with an ?2a antagonist to achieve specific stimulation of the ?2c receptor. Pharmaceutical compositions, kit-of-parts and therapeutic systems comprising said agonists/antagonists as active agents are objects of the present invention.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 28, 2020
    Assignee: ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)
    Inventors: Grégoire Courtine, Quentin Barraud, Pavel Musienko
  • Patent number: 10632083
    Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: April 28, 2020
    Assignee: SaCSh Corp.
    Inventor: Uri Shabto
  • Patent number: 10624339
    Abstract: There is provided a method of controlling filbertworm capable of reducing the number of release positions without changing a dosage amount per unit area. More specifically, there is provided a method of controlling filbertworm comprising the step of: providing E,E-8,10-dodecadienyl acetate or a composition comprising 80% by weight or more of E,E-8,10-dodecadienyl acetate at 1 to 100 release positions/ha to release the E,E-8,10-dodecadienyl acetate at a release rate of from 0.01 to 5 g/day/ha for mating disruption.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: April 21, 2020
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Tatsuya Hojo, Erina Ohno, Naoki Ishibashi
  • Patent number: 10626126
    Abstract: There are provided 5,6-dihydro-4H-dithieno[3,2-b:2?,3?-d]azepine derivatives(as defined in the disclosure) which are useful in the treatment of RSV infection and for the prevention of disease associated with RSV infection.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: April 21, 2020
    Assignee: PULMOCIDE LIMITED
    Inventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Jennifer Claire Thomas, Peter John Murray, Matthew Stephen Coates, Daniel William Brookes, Kazuhiro Ito, Peter Strong
  • Patent number: 10610499
    Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 7, 2020
    Assignee: SaCSh Corp.
    Inventor: Uri Shabto
  • Patent number: 10597606
    Abstract: A method for producing monovalent unsaturated free fatty acids having 20 and/or 22 carbons or low-grade alcohol esters thereof, said method involving the following: obtaining free fatty acids or low-grade alcohol esters through the hydrolysis or alcoholysis of oils and fats derived from marine products; carrying out distillation on the free fatty acids or low-grade alcohol esters, and reducing the concentration of fatty acids with 18 or less carbons in the low-grade alcohol esters or free fatty acids; and collecting fractions of monovalent unsaturated free fatty acids having 20 and/or 22 carbons or low-grade alcohol esters thereof by column chromatography based on reversed-phase distribution.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 24, 2020
    Assignee: Nippon Suisan Kaisha, Ltd.
    Inventors: Seizo Sato, Takuro Fukae, Naomi Ohtsuka, Hideaki Yamaguchi
  • Patent number: 10576077
    Abstract: The present disclosure relates to the preparation of polymorphic mixtures of Cepharanthine.2HCl. Mixtures of at least two polymorphic forms can be formed into a mobile liquid phase in organic/aqueous solvent mixtures along with enteric polymer that can be spray dried to produce solid particulate enteric formulations for medicinal drug-treatment applications.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: March 3, 2020
    Assignee: Southwest Research Institute
    Inventors: William E. Bauta, Joseph A. McDonough, Hong Dixon, Stephen T. Wellinghoff, Kevin Fitzpatrick
  • Patent number: 10570095
    Abstract: 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is useful in the modulation of blood or serum uric acid levels. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used in the treatment or prevention of disorders related to aberrant levels of uric acid. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used for reducing serum uric acid levels in a human. Also described herein are compositions comprising 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, and their use in the modulation of blood or serum uric acid levels.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 25, 2020
    Assignee: Ardea Biosciences, Inc.
    Inventors: Li-Tain Yeh, Barry D. Quart
  • Patent number: 10532102
    Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: January 14, 2020
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, ChiaTing Huang, John Mao
  • Patent number: 10525009
    Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 7, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Itzhak E. Lerner, Moshe Flashner-Barak, Erwin v Achthoven, Hans Keegstra, Ruud Smit
  • Patent number: 10507209
    Abstract: The invention relates to quinazoline derivatives substituted by aniline which are represented by the below formula (I), pharmaceutical acceptable salts and stereoisomer thereof, wherein these groups of R1, R2, R3, R4, R5, R6, L and n have the meanings given in the specification. The invention also relates to preparation methods, pharmaceutical compositions, pharmaceutical preparation and the use for preparation of medicine of treating excessive hyperplasia and chronic obstructive pulmonary disease and uses for treating excessive hyperplasia and chronic obstructive pulmonary disease thereof.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 17, 2019
    Assignee: XUANZHU PHARMA CO, LTD.
    Inventors: Yanyan Dong, Chengkon Shih
  • Patent number: 10492495
    Abstract: An agrochemical composition contains a component (A): a compound represented by formula (I) (wherein, R1, R2, R3a, R3b, R4a, R4b, and R5 each independently represents an unsubstituted or substituted C1-6 alkyl group or the like, n represents an integer of 0 to 4, o and p each independently represents an integer of 2 to 4, and X represents a carbon atom or a nitrogen atom) or a salt thereof, and a component (B): a hydrolysis inhibitor.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: December 3, 2019
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Tetsutaro Kai, Eriko Okada, Takahiro Maekawa
  • Patent number: 10493033
    Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: December 3, 2019
    Assignee: GRÜNENTHAL GMBH
    Inventors: Lutz Barnscheid, Eric Galia, Sebastian Schwier, Ulrike Bertram, Anja Geissler, Kornelia Griessmann, Johannes Bartholomäus
  • Patent number: 10485786
    Abstract: The present invention provides a pharmaceutical composition for preventing or treating macular degeneration, which comprises benzopyran derivatives substituted with secondary amines including imidazole or pharmaceutically acceptable salts thereof as an active ingredient. The pharmaceutical composition of the present invention may be used in the form of eye drops.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: November 26, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kyu-Yang Yi, Sung-Eun Yoo, Nack-Jeong Kim, Jee-Hee Suh, Choun-Ki Joo, Jun-Sub Choi, Jae-Sik Yang, Geun-Hyeog Lee, Yun-Seok Cho, Jin-Ha Park, Hye-Sung Lee
  • Patent number: 10471075
    Abstract: This disclosure generally relates to methods for reducing the risk of preterm birth in a pregnant human female patient that include subcutaneous administration of HPC. The disclosure relates in part to the discovery that subcutaneous administration of HPC is actually feasible and can result in sufficient plasma levels of HPC in pregnant patients that can reduce the risk of preterm birth.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: November 12, 2019
    Assignee: AMAG PHARMACEUTICALS, INC.
    Inventors: Robert Birch, Michael J. Jozwiakowski
  • Patent number: 10463636
    Abstract: The present application relates to strontium L-lactate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable strontium to mammals and treating or preventing symptoms of bone and/or cartilage disorders.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: November 5, 2019
    Inventor: Deanna J. Nelson
  • Patent number: 10456390
    Abstract: A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist-?2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: October 29, 2019
    Assignee: Almirall, S.A.
    Inventors: Monica Aparici Virgili, Marta Calbet Murtro, Montserrat Miralpeix Guell, Amadeu Gavalda Monedero, Carlos Puig Duran
  • Patent number: 10449183
    Abstract: The invention relates to methods and pharmaceutical compositions for inhibiting or preventing preterm birth, inhibiting or delaying cervical ripening, inhibiting myometrial contractility and treating or inhibiting uterine contractility disorders. The methods comprise administering an effective amount of a composition comprising steroid hormones such as soluble progesterone.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: October 22, 2019
    Assignee: Dignity Health
    Inventors: Robert Garfield, Shao-Qing Shi, Leili Shi
  • Patent number: 10426787
    Abstract: Topical pharmaceutical compositions comprise a combination of a corticosteroid and a retinoid; and methods for treating psoriasis with same. In one embodiment, the corticosteroid comprises halobetasol propionate, and the retinoid comprises tazarotene.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: October 1, 2019
    Assignee: Bausch Health US, LLC
    Inventors: Gordon J. Dow, Radhakrishnan Pillai, Varsha D. Bhatt